Fulltext

The mTOR Pathway in Breast Cancer

Hynes, Nancy ; Boulay, Anne

In: Journal of Mammary Gland Biology and Neoplasia, 2006, vol. 11, no. 1, p. 53-61

Ajouter à la liste personnelle
    Titre
    • The mTOR Pathway in Breast Cancer
    Auteur
    • Hynes, Nancy. Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH-4058, Basel, Switzerland
    • Boulay, Anne. Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH-4058, Basel, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Journal of Mammary Gland Biology and Neoplasia, 2006, vol. 11, no. 1, p. 53-61. Kluwer Academic Publishers-Plenum Publishers; http://www.springer-ny.com
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:320874
    Summary
    There is currently a wealth of information regarding the mutations that contribute to cancer development. Most of these mutations alter the expression and activity of signal transduction proteins. The current goal in cancer therapy is to use our knowledge of the molecular alterations in a cancer cell to choose the most appropriate signal transduction inhibitor for an individual patient. The topic of this review is the mammalian target of rapamycin (mTOR) kinase signaling pathway, which is aberrantly activated in many types of human cancer. We will discuss the mTOR pathway and the potential mechanisms that contribute to its activation in cancer, together with data relating to the potential for inhibitors targeting the mTOR-signaling pathway to impact on breast cancer therapy